Knight Announces Normal Course Issuer Bid

Core Viewpoint - Knight Therapeutics Inc. has announced the acceptance of its Notice of Intention to Make a Normal Course Issuer Bid (NCIB) to repurchase up to 3,000,000 common shares, representing approximately 3% of its outstanding shares, over the next 12 months [1][3] Group 1: NCIB Details - The NCIB allows the company to purchase shares from August 22, 2025, to August 21, 2026, with a maximum daily purchase limit of 15,823 shares [1] - The company previously obtained approval to buy up to 5,312,846 shares and has already repurchased 2,019,906 shares at a weighted average price of $5.48 in the past twelve months [1] Group 2: Automatic Share Purchase Plan - Knight has entered into an automatic share purchase plan with a broker to facilitate share repurchases under the NCIB, allowing purchases during regulatory restrictions or blackout periods [2] - The plan has been pre-cleared by the TSX and will be effective from August 22, 2025 [2] Group 3: Company Perspective - The company believes that the market price of its common shares may not reflect its inherent value, making the share repurchase an appropriate use of funds [3] Group 4: Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, focused on acquiring and commercializing pharmaceutical products for Canada and Latin America [4] - The company's shares are traded on the TSX under the symbol GUD [4]